Compare Amgen's income of 17bn to Johnson and Johnson 67bn and the thirteen major pharmaceutical companies in between. What is it going to cost those 15 companies if they don't win Partry's seven year patents as well as the R&D for the other products.
A lot less than paying overs for every small bio company with potential. PAB may well be a takeover target one day but not where they are currently at in their development.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
-0.001(50.0%) |
Mkt cap ! $2.365M | |||
| Open | High | Low | Value | Volume |
| 0.1¢ | 0.2¢ | 0.1¢ | $7.467K | 4.095M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 46 | 115294083 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 52771391 | 23 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PAB (ASX) Chart |